-

Akili to Participate in LifeSci Partners HealthTech Symposium

BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that management will present at a fireside chat and participate in a panel discussion on prescription digital therapeutics at the virtual LifeSci Partners HealthTech Symposium on Tuesday, September 20, 2022.

Details are as follows:

Format: Presentation and Fireside Chat
Time: 9:30 a.m. ET

Format: Panel Discussion
Topic: Prescription Digital Therapeutics
Time: 11:30 a.m. ET

Live and archived webcasts of the fireside chat and panel discussion will be available on the Investors section of Akili’s website at www.akiliinteractive.com.

About Akili

Akili is pioneering the development of cognitive treatments through game-changing technologies. Our approach of leveraging technologies designed to directly target the brain establishes a new category of medicine – medicine that is validated through clinical trials like a drug or medical device but experienced like entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through rigorous clinical programs. Driven by Akili’s belief that effective medicine can also be fun and engaging, Akili’s products are delivered through captivating action video game experiences. For more information, please visit www.akiliinteractive.com.

Contacts

Investor Contact:
Joshua Young
VP of Investor Relations
jyoung@akiliinteractive.com

Media Contact:
Julie DiCarlo
SVP, Communications
julie@akiliinteractive.com

Industry:

AKILI INTERACTIVE

NASDAQ:AKLI
Details
Headquarters: Boston, MA
CEO: Eddie Martucci
Employees: 80-90
Organization: PRI
Release Versions
English

Contacts

Investor Contact:
Joshua Young
VP of Investor Relations
jyoung@akiliinteractive.com

Media Contact:
Julie DiCarlo
SVP, Communications
julie@akiliinteractive.com

More News From AKILI INTERACTIVE

Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video Game

BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital therapeutics company, today announced U.S. Food and Drug Administration (FDA) clearance of EndeavorOTCⓇ (AKL-T01) as an over-the-counter treatment for adults with attention-deficit/hyperactivity disorder (ADHD). Delivered through an engaging video game experience, EndeavorOTC is indicated to improve attention function as measured by computer-based testing in men and women with primarily inattentive or combined-type ADHD, who...

Akili Reports First Quarter 2024 Financial Results and Provides Business Update

BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter ended March 31, 2024 and provided an update on business progress. As announced in late April 2024, the Company’s board of directors has initiated a process that is currently ongoing to evaluate potential strategic alternatives to maximize shareholder value. “We are working expeditiously with our board of directors and our external advisors and look forwar...

Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results

BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today provided several corporate updates, including an amendment to its strategic distribution agreement with Shionogi & Co., Ltd. (“Shionogi”), a leading global pharmaceutical company. Under the terms of the amended agreement, Shionogi has canceled and forgiven a $5.0 million long-term debt obligation and agreed to make certain payments for SDT-001 (the Japanese, localized version of Akili’s AKL-T01 di...
Back to Newsroom